Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Single dose NTBC‐treatment of hereditary tyrosinemia type I

Schlune, A., Thimm, E., Herebian, D., Spiekerkoetter, U. · 2012 · Journal of Inherited Metabolic Disease

Abstract

NTBC (2‐(2‐nitro‐4‐trifluoromethylbenzoyl)‐1,3cyclohexanedione) is the mainstay of treatment in tyrosinemia type 1 (HT 1). The current recommendation is to divide the total daily dose of NTBC into two doses. We monitored the plasma NTBC concentrations in a series of seven patients who were changed from multiple divided doses to a single daily dose of NTBC. Two additional patients were started on a single daily dose of NTBC after the diagnosis of HT 1 was established. In three patients, NTBC kinetics were performed over 6 and 24 hours, respectively. The use of multiple divided doses or a single daily dose did not significantly affect plasma NTBC concentrations or the mean daily dose needed to attain therapeutic plasma NTBC concentrations. Moreover, kinetic studies demonstrated that plasma NTBC concentrations were completely stable over a period of 24 hours with a single dose regimen, as expected given the known NTBC plasma half life of 54 hours. Although these preliminary results need to be confirmed in more patients, our findings show that administration of NTBC in a single daily dose may be as effective as a multiple‐dose regimen in reaching therapeutic plasma NTBC concentrations and suppressing succinylacetone formation in patients with HT 1. In fact, single dose treatment may increase patients’ compliance with the drug treatment and improve metabolic control.

Overview

Integrity signals

Registry

Crossref · 10.1007/s10545-012-9450-9

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 22 references

Research works printed but not linked: 1

  1. Orfadin [package insert], 2010, Swedish Orphan Biovitrium International AB

Cited by

See all 33

Metadata

Authors
Schlune, A., Thimm, E., Herebian, D., & Spiekerkoetter, U.
Affiliations
Düsseldorf University Hospital (DE)
Corresponding author
Schlune, A.
Venue
Journal of Inherited Metabolic Disease
Publisher
Wiley
Published
2012-02-04
Volume
35
Issue
5
Pages
831-836
ISSN
  • 0141-8955 (ISSN-L)
  • 1573-2665
OpenAlex
W2041258761
Cited by
33
References
22
Citations by year
2026: 1 · 2025: 1 · 2024: 2 · 2022: 2 · 2021: 1 · 2020: 6 · 2019: 2 · 2018: 4 · 2017: 5 · 2015: 2 · 2014: 4 · 2013: 3
FWCI
1.85
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Inherited Metabolic Disease (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
  • Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
Keywords
NTBC, tyrosinemia type I, once-daily dosing, dosing regimen, pharmacokinetics, succinylacetone, medication adherence, metabolic control
MeSH terms
Cyclohexanones, Drug Administration Schedule, Female, Heptanoates, Humans, Infant, Infant, Newborn, Male, Nitrobenzoates, Tyrosinemias

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Single dose NTBC‐treatment of hereditary tyrosinemia type I. https://app.cochat.ai/papers/10.1007/s10545-012-9450-9
The paper
Schlune, A., Thimm, E., Herebian, D., & Spiekerkoetter, U. (2012). Single dose NTBC‐treatment of hereditary tyrosinemia type I. Journal of Inherited Metabolic Disease. https://doi.org/10.1007/s10545-012-9450-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.